PAPER Gröger A, Kolb R, Schäfer R, Klose U
SEARCH RESULTS
329930 RESULTS
PAPER Li D, Liu Q, Jia D, Dou D, Wang X, Kang T
Protective Effect of Arctigenin against MPP+ and MPTP-induced Neurotoxicity.
Planta Med. 2014 Jan;80(1):48-55. Epub 2014 Jan 10 PubMed: 24414307PAPER Sikiö M, Holli-Helenius KK, Harrison LC, Ryymin P, Ruottinen H, Saunamäki T, Eskola HJ, Elovaara I, Dastidar P
MR image texture in Parkinson's disease: a longitudinal study.
Acta Radiol. 2014 Jan 10; PubMed: 24413223PAPER Stoessl AJ
Gene therapy for Parkinson's disease: a step closer?
Lancet. 2014 Mar 29;383(9923):1107-9. Epub 2014 Jan 10 PubMed: 24412047PAPER Gan J, Zhou M, Chen W, Liu Z
Non-motor symptoms in Chinese Parkinson's disease patients.
J Clin Neurosci. 2014 May;21(5):751-4. Epub 2013 Sep 11 PubMed: 24411328PAPER Salvatore MF
ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.
J Neurochem. 2014 May;129(3):548-58. Epub 2014 Jan 27 PubMed: 24410633PAPER Seet RC, Lim EC, Tan JJ, Quek A, Chow A, Chong WL, Ng M, Ong CN, Halliwell B
Effects of high-dose coenzyme Q10 on biomarkers of oxidative damage and clinical outcomes in Parkinson disease.
Antioxid Redox Signal. 2014 Jan 11; PubMed: 24410614Yan-Jiang Wang
Daping Hospital, Third Military Medical UniversityChongqing, China
Ben Barres on Brain Shuttle Ferries Antibodies Across the Blood-Brain Barrier
COMMENT Niewoehner and colleagues set out to further improve approaches around targeting the transferrin receptor (TfR) for brain uptake of antibodies. This study is similar to those published by others, however, it further advances the possibilities by engineeri
Dario Alessi on Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.
COMMENT This is an intriguing study. LRRK2 belongs to a class of enzymes termed “protein kinases.” LRRK2 is frequently mutated in Parkinson’s. Between 1-2 percent of Parkinson’s cases may be caused by mutations in the gene that encodes for the LRRK2 enzyme. To my
Dario Alessi
Medical Research Council Protein Phophorylation and Ubiquitylation UnitUnited Kingdom
Derya Shimshek, Martin Herzig on Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.
COMMENT The exciting findings presented here by Skibinski et al. provide key insights into the cellular role of LRRK2 in neurodegeneration underlying Parkinson’s disease (PD). The authors used a longitudinal, real-time imaging platform to individually track prima
Patrick Verstreken on Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.
COMMENT In this paper, Skibinski et al. use cellular models to assess LRRK2 toxicity. They use automated imaging to assess the time of death of large cohorts of cells and come to the interesting observation that “soluble” LRRK2 levels positively correlate with ea
Rethinking LRRK2 Toxicity: It’s How Much Is Present, Not What It Does
RESEARCH NEWS 2014-01-15 Research News Attempts to discern how mutations in the LRRK2 gene contribute to Parkinson’s disease have focused largely on the protein’s role as a kinase. In the January 8 Journal of Neuroscience, researchers led by Steven Finkbeiner at the Gladstone Ins
Joseph Foss
Cleveland ClinicCleveland, United States
Current Filters
No filters selected